GlassScriptPhysician profile
Justin Petrie
NPI 1164816443
$6,005.02
in general payments reported to CMS, 2019-2025
28 companies · $2,080 in 2025
The $2,080 reported for 2025 was more than what 89% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,182 · 2020: $322 · 2021: $268 · 2022: $146 · 2023: $664 · 2024: $1,343 · 2025: $2,080.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,087.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,086.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $1,614.90 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $944.29 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $408.46 | 2021-2025 | |
| Alkermes, INC. | $357.97 | 2019-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $356.56 | 2019-2025 | Spravato, Invega Trinza, Invega Sustenna |
| E.R. Squibb & Sons, L.L.C. | $304.97 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $256.34 | 2024-2025 | Uzedy, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $248.04 | 2022-2025 | Caplyta |
| Axsome Therapeutics, INC. | $215.79 | 2023-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $212.29 | 2019-2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $186.32 | 2020-2025 | Trintellix |
| Almatica Pharma LLC | $161.01 | 2024-2025 | Loreev Xr |
| Sunovion Pharmaceuticals INC. | $119.98 | 2019 | |
| Dexcom, INC. | $113.67 | 2023 | Dexcom G6 Transmitter |
| Lundbeck LLC | $77.71 | 2019-2025 | Rexulti |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $62.72 | 2019-2020 | |
| Corium, LLC | $62.04 | 2024 | Azstarys |
| Ironshore Pharmaceuticals INC. | $57.15 | 2019-2020 | |
| Neos Therapeutics, LP | $41.39 | 2019 | |
| Bausch Health US, LLC | $37.59 | 2025 | Aplenzin |
| Sage Therapeutics, LLC | $32.98 | 2025 | Zurzuvae |
| Indivior INC. | $31.60 | 2025 | Sublocade |
| Tris Pharma INC | $21.77 | 2023 | Dyanavel Xr |
| Neuronetics, INC. | $19.26 | 2023 | Neurostar Tms Therapy System |
| Idorsia Pharmaceuticals US INC | $16.56 | 2023 | Quviviq |
| Shire North American Group INC | $16.38 | 2019 | |
| Supernus Pharmaceuticals, INC. | $16.26 | 2025 | Qelbree |
| Arbor Pharmaceuticals, INC. | $11.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Petrie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.